Next-gen CAR-T, TCR player Autolus gains $80M for clinical trial work
Autolus has gone back to the well to draw up an $80 million C round designed to push the next-gen CAR-T player through a key …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
